Identifying and managing genetic mutations of high-risk individuals and their family members before they develop cancer will save lives. Medneon's mission is to address this large unmet need.
The innovative Medneon digital AI platform curates up-to-date, actionable and personalized information regarding an individual's risk of developing cancer and generates insights on appropriate preventive and management strategies over time.
predictive analytics to identify and curate patients at risk who are eligible for further testing
empowers patients and physicians with decision support on how to interpret and manage abnormal genetic testing results on an individual level
virtually connects at-risk and newly diagnosed patients with Medneon’s leading clinical and genetic experts
IRB approved real-world clinically annotated molecular data, impact on treatment, and patient-reported outcomes
a secure digital vault of an individual’s genetic, genomic, and clinical information that dynamically updates and enables real-time risk stratification that can be shared with family members and their providers throughout a patient’s lifetime
an expert network that consists of hundreds of Physicians, Scientists, and Researchers who are dedicated to clinicogenetics, precision prevention, and improving outcomes
We ingest and organize clinical data, genetic reports, pathology, and imaging to capture phenotypic, therapeutic, and outcomes data to understand the clinical context for each patient case by combining conventional numerical AI techniques with advanced symbolic reasoning to provide human-like insights.
Medneon Launches Landmark Patient Registry on Use of Predictive Genetics to Prevent Breast Cancer. Millions of U.S. women have a high risk of developing breast cancer but most have not been identified
CUPERTINO Calif. -- Medneon, a digital health company, today announced the launch of a groundbreaking clinicogenetic patient registry to investigate whether identifying high-risk individuals and managing their genetic mutations over time can prevent hereditary breast cancer...More
Join us at ASBrS 2019 Annual Meeting April 30 – May 5 in Dallas, TX, Booth #353